治疗前红细胞分布宽度可能是泌尿系统癌症预后的潜在生物标志物：一项系统评价和荟萃分析。
Pretreatment red blood cell distribution width may be a potential biomarker of prognosis in urologic cancer: a systematic review and meta-analysis.
作者信息
Cao Wei, Shao Yifeng, Wang Na, Jiang Zhichao, Yu Sun, Wang Jinguo
机构信息
The First Hospital of Jilin University, Changchun, Jilin, 130021, People's Republic of China.
出版信息
Biomark Med. 2022 Dec;16(18):1289-1300. doi: 10.2217/bmm-2022-0409. Epub 2023 Mar 13.
To demonstrate the prognostic value of pretreatment red blood cell distribution width (RDW) in patients with urological cancer. We searched the relevant literature on Web of Science, Cochrane Central Register of Controlled Trials, PubMed, Embase, Sinomed databases and Chinese National Knowledge Infrastructure up to 30 March 2022, to investigate the relationship between RDW levels and the prognosis of patients with urological tumors. This study comprised 15 retrospective studies involving 9492 patients. Increased pretreatment RDW was associated with poorer overall survival (hazard ratio [HR]: 1.52; 95% CI: 1.27-1.82; p < 0.001), cancer-specific survival (HR: 1.34; 95% CI: 1.15-1.57; p < 0.001) and progression-free survival (HR: 1.53; 95% CI: 1.26-1.86; p < 0.001). High pretreatment RDW might predict poor survival for patients with urologic cancers.
为了证明治疗前红细胞分布宽度（RDW）在泌尿系统癌症患者中的预后价值。我们检索了截至2022年3月30日Web of Science、Cochrane对照试验中心注册库、PubMed、Embase、中国生物医学文献数据库和中国知网数据库中的相关文献，以研究RDW水平与泌尿系统肿瘤患者预后之间的关系。本研究包括15项回顾性研究，涉及9492例患者。治疗前RDW升高与较差的总生存期（风险比[HR]：1.52；95%置信区间：1.27-1.82；p<0.001）、癌症特异性生存期（HR：1.34；95%置信区间：1.15-1.57；p<0.001）和无进展生存期（HR：1.53；95%置信区间：1.26-1.86；p<0.001）相关。治疗前高RDW可能预示泌尿系统癌症患者生存期较差。
Zotero 插件